Klotho Neuroscience Inc. $(KLTO)$, a US-based biogenetics company, has announced a new clinical study in collaboration with the Okinawa Research Center for Longevity Science (ORCLS). The study aims to investigate the role of the human Klotho gene and its secreted protein isoform (s-KL) in promoting longevity and reducing the risks of neurodegenerative diseases, including ALS, Alzheimer's Disease, and Parkinson's Disease, as well as diabetes and cardiovascular disorders. The research will initially focus on analyzing blood levels of the Klotho protein in centenarian samples collected by ORCLS over several decades. Results of this study have not yet been presented and are expected to contribute to the understanding of how maintaining optimum Klotho protein levels may protect against age-related disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.